The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and ...

The V Foundation for Cancer Research, a top-rated cancer charity, announced an exciting partnership with Cancer Vaccine ...

CytomX's CX-2051, a PROBODY® EpCAM-targeted antibody-drug conjugate (ADC), showed a 28% confirmed response rate and 5.8-month ...

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...

Noval ADC candidate ADRX-0706 received FDA Fast Track designation for advanced cervical cancer. Targeting Nectin-4 with a ...

Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...